2. Search Result
Search Result
Results for "

OGTT

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119322
    Tifenazoxide

    NN414

    		 Potassium Channel Metabolic Disease
    Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide
  • HY-102037
    SSTR5 antagonist 1

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .
    SSTR5 antagonist 1
  • HY-144289
    BMS-820132

    		Glucokinase Metabolic Disease
    BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
    BMS-820132
  • HY-173503
    DS-1150b

    		GLUT Metabolic Disease
    DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .
    DS-1150b
  • HY-119322R
    Tifenazoxide (Standard)

    NN414 (Standard)

    		 Potassium Channel Reference Standards Metabolic Disease
    Tifenazoxide (Standard) is the analytical standard of Tifenazoxide. This product is intended for research and analytical applications. Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide (Standard)
  • HY-179419
    Glucokinase activator 10

    		Glucokinase Metabolic Disease
    Glucokinase activator 10, a thiazole-based compound, is a liver-selective and orally active glucokinase activator with an EC50 of 42 nM. Glucokinase activator 10 exhibits significant glucose lowering in acute diet-induced obese mouse oral glucose tolerance (OGTT) test. Glucokinase activator 10 can be used for the study of metabolic disorders .
    Glucokinase activator 10
  • HY-102037R
    SSTR5 antagonist 1 (Standard)

    		Reference Standards Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 1 (Standard) is the analytical standard of SSTR5 antagonist 1 (HY-102037). This product is intended for research and analytical applications. SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .
    SSTR5 antagonist 1 (Standard)
  • HY-160156
    SSTR5 antagonist 4

    		Somatostatin Receptor Metabolic Disease
    SSTR5 antagonist 4 (compound 1) is a potent, selective and orally active somatostatin subtype 5 (SSTR5) antagonist (hSSTR5 IC50 = 1.3 nM, mSSTR5 IC50 = 1.0 nM). SSTR5 antagonist 4 shows efficacy in mouse oral glucose tolerance test (OGTT) in high fat diet (HFD)-mice. SSTR5 antagonist 4 can be used for type 2 diabetes research .
    SSTR5 antagonist 4
  • HY-180527
    SGLT2-IN-5

    		SGLT Dipeptidyl Peptidase Metabolic Disease
    SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes .
    SGLT2-IN-5
  • HY-182729
    FFA2 agonist-2

    		Free Fatty Acid Receptor Metabolic Disease
    FFA2 agonist-2 is a potent agonist of the FFA2 (GPR43) receptor, with a pEC50 of 7.9 for human FFA2, and a pEC50 of 7.3 for murine FFA2. FFA2 agonist-2 acts as an orthosteric agonist and shows no obvious cross‑activity against FFA1, FFA3 and FFA4. FFA2 agonist-2 can be used for FFA2 receptor research in type 2 diabetes and metabolic disorders .
    FFA2 agonist-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: